Canaccord


Canaccord Maintains Buy On Hain Celestial Following Solid 4Q14 And Guides Above For F2015

In a research note released today, Canaccord analyst Scott Van Winkle maintained a Buy rating on Hain Celestial Group (NASDAQ:HAIN) with a $108 price target, following the company’s fourth-quarter …

Canaccord Maintains Buy On IMAX Following JV Arrangement Expansion With AMC

Imax Corporation (IMAX) announced this morning the expansion of its JV arrangement with AMC by a further 11 theatres. The contract term is 13 years.

Canaccord Reiterates Outperform On AMD Following Investor Meetings; Keeps $4.50 Price Target

In a research report issued today, Canaccord analyst Matthew Ramsay reiterated an Outperform rating on Advanced Micro Devices (AMD) with a $4.50 price target, following investor meetings with AMD’s Corporate …

Lannett: Oxycodone Hydrochloride Approval Incremental Plus, Says Canaccord

In a research report released today, Canaccord analyst John Newman reiterated coverage with a Buy rating on Lannett Company (LCI), and a $55.00 price target.

Canaccord Maintains Hold On DragonWave Following Public Offering

In a research note released today, Canaccord Genuity analyst Robert Young maintained a Hold rating on Dragonwave Inc (DRWI) with a $2 price target. The note follows yesterday’s news …

Canaccord Slightly Raises Price Target On Deckers Outdoor Following Solid FQ1 Results

In a research report issued today, Canaccord analyst Camilo Lyon reiterated a Buy rating on shares of Deckers Outdoor (DECK) and raised his price target to $106 (from $103), following DECK’s …

Canaccord Reiterates Buy On Salix Following The Merger With Cosmo’s Irish Unit

In a research note released today, Canaccord analyst Corey Davis reiterated coverage with a Buy rating on shares of Salix Pharmaceuticals (SLXP) and a $161.00 price target, following yesterday’s news of a definitive merger agreement …

Canaccord Reiterates Buy Rating On Abraxas Petroleum, Sees 16% Upside For The Stock

In a research report published yesterday, Canaccord analyst Stephen Berman maintained a Buy rating on Abraxas Petroleum (AXAS), and a $7 price target, which represents a potential upside of 16% from where the …

Canaccord Initiates Buy On Abengoa; Sees 31% Potential Upside For Stock

In a research report published yesterday, Canaccord Genuity analyst John Quealy initiated coverage on Abengoa Yield (ABY) shares. Quealy issued a Buy rating …

STAAR Surgical: Warning Letter Is A Setback, But A Manageable One, Says Canaccord

In a research note published Tuesday, Canaccord analyst Jason Mills maintained a Buy rating on STAAR Surgical Company (STAA) with a price target of $21.00, after STAA received a warning letter from FDA …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts